CA3152988A1 - Oxytocin compositions for treatment of tinnitus - Google Patents

Oxytocin compositions for treatment of tinnitus Download PDF

Info

Publication number
CA3152988A1
CA3152988A1 CA3152988A CA3152988A CA3152988A1 CA 3152988 A1 CA3152988 A1 CA 3152988A1 CA 3152988 A CA3152988 A CA 3152988A CA 3152988 A CA3152988 A CA 3152988A CA 3152988 A1 CA3152988 A1 CA 3152988A1
Authority
CA
Canada
Prior art keywords
oxytocin
composition
tinnitus
thickener
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3152988A
Other languages
English (en)
French (fr)
Inventor
Lawrence C. Newman
James CRAMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maskbegone LLC
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of CA3152988A1 publication Critical patent/CA3152988A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3152988A 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus Pending CA3152988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893363P 2019-08-29 2019-08-29
US62/893,363 2019-08-29
PCT/US2020/048736 WO2021042029A1 (en) 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus

Publications (1)

Publication Number Publication Date
CA3152988A1 true CA3152988A1 (en) 2021-03-04

Family

ID=74680528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3152988A Pending CA3152988A1 (en) 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus

Country Status (7)

Country Link
US (1) US11241477B2 (https=)
EP (1) EP4021410A4 (https=)
JP (1) JP2022546703A (https=)
AU (1) AU2020335930B2 (https=)
BR (1) BR112022003687A2 (https=)
CA (1) CA3152988A1 (https=)
WO (1) WO2021042029A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus
US20250255930A1 (en) * 2024-02-08 2025-08-14 Maskbegone Llc Methods of treatment of tinnitus using derivatives of oxytocin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5276982B2 (ja) * 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
EP2571360A4 (en) * 2010-05-19 2013-07-31 Univ North Carolina METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS
US11744838B2 (en) * 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10940277B2 (en) 2014-11-19 2021-03-09 Optinose As Intranasal administration
SG11201705591PA (en) * 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use

Also Published As

Publication number Publication date
WO2021042029A1 (en) 2021-03-04
EP4021410A4 (en) 2023-12-06
BR112022003687A2 (pt) 2022-05-24
AU2020335930B2 (en) 2025-06-05
AU2020335930A1 (en) 2022-03-24
US11241477B2 (en) 2022-02-08
US20210060119A1 (en) 2021-03-04
EP4021410A1 (en) 2022-07-06
JP2022546703A (ja) 2022-11-07

Similar Documents

Publication Publication Date Title
JP7756953B2 (ja) マグネシウム含有オキシトシン製剤および使用の方法
US20030072793A1 (en) Method for administering agents to the central nervous system
US10987423B2 (en) Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
EP1135105B1 (en) Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
US11241477B2 (en) Oxytocin compositions for treatment of tinnitus
RU2010133870A (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
WO2025171305A1 (en) Methods of treatment of tinnitus using derivatives of oxytocin
US20260053883A1 (en) Oxytocin compositions for treatment of visual snow syndrome
US20070020195A1 (en) Nasally administered appetite suppressants
US20230000796A1 (en) Intranasal administration of ketamine to cluster headache patients
JP2015533167A (ja) 局所用ビタミンｄ口腔サプリメント組成物
US6645532B1 (en) Compositions and method for relieving discomfort in the ears
JP7155116B2 (ja) 女性の性機能障害を治療する医薬組成物および方法
US10092630B2 (en) Methods of treating anorexia nervosa by intranasal administration of insulin
US20140179597A1 (en) Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction
EP3906934A1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
Class et al. Patent application title: Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction Inventors: Steven Lehrer (New York, NY, US)
US20230190878A1 (en) Beta thymosin peptides for treating viral infections
CA3074215A1 (en) Use of insulin for the treatment of epilepsy, seizure disorders and sudden unexpected death in epilepsy
GB2417202A (en) Pharmaceutical preparation comprising calcitonin

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240821

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240821

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241025

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241025

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250410

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250917